- Home
- ROIV vs CWAN Comparison
ROIV vs CWAN Comparison
Compare ROIV & CWAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- CWAN
- Stock Information
- Founded
- ROIV 2014
- CWAN 2004
- Country
- ROIV United Kingdom
- CWAN United States
- Employees
- ROIV N/A
- CWAN N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- CWAN Computer Software: Prepackaged Software
- Sector
- ROIV Health Care
- CWAN Technology
- Exchange
- ROIV Nasdaq
- CWAN Nasdaq
- Market Cap
- ROIV 8.4B
- CWAN 7.3B
- IPO Year
- ROIV N/A
- CWAN 2021
- Fundamental
- Price
- ROIV $10.76
- CWAN $24.32
- Analyst Decision
- ROIV Buy
- CWAN Buy
- Analyst Count
- ROIV 4
- CWAN 9
- Target Price
- ROIV $17.50
- CWAN $32.44
- AVG Volume (30 Days)
- ROIV 5.9M
- CWAN 3.5M
- Earning Date
- ROIV 05-29-2025
- CWAN 04-30-2025
- Dividend Yield
- ROIV N/A
- CWAN N/A
- EPS Growth
- ROIV N/A
- CWAN N/A
- EPS
- ROIV N/A
- CWAN 1.71
- Revenue
- ROIV $122,585,000.00
- CWAN $475,948,000.00
- Revenue This Year
- ROIV N/A
- CWAN $21.92
- Revenue Next Year
- ROIV N/A
- CWAN $18.92
- P/E Ratio
- ROIV N/A
- CWAN $14.23
- Revenue Growth
- ROIV 140.04
- CWAN 23.21
- 52 Week Low
- ROIV $8.73
- CWAN $17.42
- 52 Week High
- ROIV $13.06
- CWAN $35.71
- Technical
- Relative Strength Index (RSI)
- ROIV 49.33
- CWAN 56.68
- Support Level
- ROIV $10.58
- CWAN $22.89
- Resistance Level
- ROIV $11.77
- CWAN $24.63
- Average True Range (ATR)
- ROIV 0.34
- CWAN 0.71
- MACD
- ROIV -0.05
- CWAN 0.35
- Stochastic Oscillator
- ROIV 15.13
- CWAN 88.79
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CWAN Clearwater Analytics Holdings Inc.
Clearwater Analytics Holdings Inc provides a SaaS solution for automated investment data aggregation, reconciliation, accounting and reporting services to insurers, investment managers, corporations, institutional investors and government entities. It earns revenue from providing access to its SaaS platform to customers, services that support the implementation on the SaaS platform, selling perpetual and term-based software licenses and providing maintenance and support and professional services under contracts with customers. The majority of the revenue is earned in the United States.